Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Granella

Showing results (51-60 of 112) with videos related to

Pageof 12
Sort By:
Neurology. Clinical Practice|April 23, 2016
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis, et al.
JAMA Neurology|February 10, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosisAnna He, Tim Spelman, Vilija Jokubaitis, et al.
JAMA Neurology|July 25, 2022
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple SclerosisEmilio Portaccio, Mattia Fonderico, Pietro Iaffaldano, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategiesPietro Iaffaldano, Giuseppe Lucisano, Francesca Caputo, et al.
Neuroepidemiology|May 9, 2021
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, ItalyElisa Baldin, Corrado Zenesini, Ippazio Cosimo Antonazzo, et al.
Journal of Neurology|February 17, 2024
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT)Alessia Bianchi, Domenica Matranga, Francesco Patti, et al.
Brain : a Journal of Neurology|March 24, 2022
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort studyEmilio Portaccio, Angelo Bellinvia, Mattia Fonderico, et al.
Brain : a Journal of Neurology|September 13, 2015
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Carlo Pozzilli, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Neurology|November 24, 2025
Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying TreatmentsErmelinda De Meo, Ilaria Addazio, Emilio Portaccio, et al.
Pageof 12

Showing results (51-60 of 112) with videos related to

Sort By:
Pageof 12
Neurology. Clinical Practice|April 23, 2016
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis, et al.
JAMA Neurology|February 10, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosisAnna He, Tim Spelman, Vilija Jokubaitis, et al.
JAMA Neurology|July 25, 2022
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple SclerosisEmilio Portaccio, Mattia Fonderico, Pietro Iaffaldano, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategiesPietro Iaffaldano, Giuseppe Lucisano, Francesca Caputo, et al.
Neuroepidemiology|May 9, 2021
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, ItalyElisa Baldin, Corrado Zenesini, Ippazio Cosimo Antonazzo, et al.
Journal of Neurology|February 17, 2024
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT)Alessia Bianchi, Domenica Matranga, Francesco Patti, et al.
Brain : a Journal of Neurology|March 24, 2022
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort studyEmilio Portaccio, Angelo Bellinvia, Mattia Fonderico, et al.
Brain : a Journal of Neurology|September 13, 2015
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Carlo Pozzilli, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Neurology|November 24, 2025
Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying TreatmentsErmelinda De Meo, Ilaria Addazio, Emilio Portaccio, et al.
Pageof 12